Resource Library

Although eConsent struggled to gain momentum and wider acceptance pre-pandemic, it’s now a major part of clinical research. In this article, learn three ways eConsent addresses the requirements for valid informed consent.

DTx represent an emerging field of software-driven, evidence-based products intended to “prevent, manage, or treat a medical disease or disorder.” Cybersecurity is a concern for DTx, whether they are being evaluated through clinical research or are aiming at market release.

Learn how a remote-first approach to dermatology trials can streamline enrollment, increase patient retention, and ensure data quality.

Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally.

At Castor, we hope to see DCT extend into all trials as we work alongside researchers in the pursuit of the ultimate goal of democratized clinical research.

announced two executive appointments to accelerate the company’s growth and impact on the industry. Kimberly Tableman as Chief Clinical Development Officer (CCDO) and Anna Wozniak as Chief Financial & Development Officer (CFDO).

Since it was first instituted in the 1960s, written consent to participate in research studies has undergone very little change other than tightening regulations and increased participant education of their rights.

Decentralized clinical trials (DCT) are collecting many kinds of data remotely, and this data is only expected to grow in volume. From wireless patches monitoring vitals to an ever-growing list of mobile-connected products, there are new data sources popping up almost everywhere.

eConsent accelerates enrollment, increases retention, and reduces site burden. Find out why it’s the way of the future for clinical trials here.

Download this case study to learn how Castor responded to the disruptive impact of COVID-19 and helped the COVID-RED study implement decentralized clinical trial methods to recruit over 17,825 participants in just 15 weeks.